11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth ManagementDefense World · 1 day ago
Halozyme to Report Third Quarter 2026 Financial and Operating ResultsPRNewsWire · 4 days ago
5 Strong Buy Growth Stocks With High Margins to Grab Before EarningsZacks Investment Research · 4 days ago
Halozyme's Strong Earnings Growth Sends Shares HigherFXEmpire · 5 days ago
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.Defense World · Oct 18, 2026
5 Stocks to Buy Using the Relative Price Strength StrategyZacks Investment Research · Oct 16, 2026Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $1.79 | $2.28 | Beat |
| May 11, 2026 | $1.55 | $1.60 | Beat |
| Feb 17, 2026 | $2.15 | -$0.24 | Miss |
| Nov 3, 2025 | $1.63 | $1.72 | Beat |
| Aug 5, 2025 | $1.23 | $1.54 | Beat |
| May 6, 2025 | $0.95 | $1.11 | Beat |